AstraZeneca PLC (AZN) Price CAGR:23.00%(TTM)
Over the latest trailing 12-month period, AstraZeneca PLC (AZN)'s price cagr is +23.00%. The comparable SPY value is +22.70%. Year-to-date price return is -0.22%. Price CAGR uses adjusted close price history and excludes dividends.
Over longer horizons, AstraZeneca PLC's Price CAGR averages 6.86% over 3 years and 9.10% over 5 years. The price CAGR (Compound Annual Growth Rate) shows how AstraZeneca PLC's stock price has grown over various time periods. This measures pure price appreciation without including dividends.
AZN Price CAGR Chart
AstraZeneca PLC (AZN)
AZN Quarterly Price (YoY)
Price growth vs the same quarter one year earlier, last 20 quarters.
AZN Price CAGR History
| Year | Start Price | End Price | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | 158.16 | 139.76 | -18.40 | -11.63% | -11.63% |
| 2024 | 142.75 | 158.16 | +15.41 | +10.80% | +10.80% |
| 2023 | 126.70 | 142.75 | +16.05 | +12.67% | +12.67% |
| 2022 | 116.23 | 126.70 | +10.47 | +9.01% | +9.01% |
| 2021 | 107.67 | 116.23 | +8.56 | +7.95% | +7.95% |
| 2020 | 82.98 | 107.67 | +24.69 | +29.75% | +29.75% |
| 2019 | 69.05 | 82.98 | +13.93 | +20.17% | +20.17% |
| 2018 | 69.76 | 69.05 | -0.71 | -1.02% | -1.02% |
| 2017 | 57.28 | 69.76 | +12.48 | +21.79% | +21.79% |
| 2016 | 67.20 | 57.28 | -9.92 | -14.76% | -14.76% |
| 2015 | 75.75 | 67.20 | -8.55 | -11.29% | -11.29% |
| 2014 | 48.28 | 75.75 | +27.47 | +56.90% | +56.90% |
| 2013 | 42.16 | 48.28 | +6.12 | +14.52% | +14.52% |
| 2012 | 49.70 | 42.16 | -7.54 | -15.17% | -15.17% |
| 2011 | 45.49 | 49.70 | +4.21 | +9.25% | +9.25% |
| 2010 | 43.86 | 45.49 | +1.63 | +3.72% | +3.72% |
| 2009 | 41.09 | 43.86 | +2.77 | +6.74% | +6.74% |
| 2008 | 51.87 | 41.09 | -10.78 | -20.78% | -20.78% |
| 2007 | 56.30 | 51.87 | -4.43 | -7.87% | -7.87% |
| 2006 | 40.50 | 56.30 | +15.80 | +39.01% | +39.01% |
| 2005 | 47.35 | 40.50 | -6.85 | -14.47% | -14.47% |
| 2004 | 45.67 | 47.35 | +1.68 | +3.68% | +3.68% |
| 2003 | 43.01 | 45.67 | +2.66 | +6.18% | +6.18% |
| 2002 | 48.71 | 43.01 | -5.70 | -11.70% | -11.70% |
| 2001 | 41.19 | 48.71 | +7.52 | +18.26% | +18.26% |
| 2000 | 40.63 | 41.19 | +0.56 | +1.38% | +1.38% |
| 1999 | 42.63 | 40.63 | -2.00 | -4.69% | -4.69% |
| 1998 | 31.79 | 42.63 | +10.84 | +34.10% | +34.10% |
| 1997 | 21.58 | 31.79 | +10.21 | +47.31% | +47.31% |
Quarterly Price: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 182 | -6.0% | +29.2% |
| Q1 2026 | 194 | +4.0% | +26.4% |
| Q4 2025 | 186 | +25.1% | +41.2% |
| Q3 2025 | 149 | +5.6% | -4.7% |
| Q2 2025 | 141 | -8.0% | -10.8% |
| Q1 2025 | 153 | +16.2% | +15.2% |
| Q4 2024 | 132 | -15.6% | +0.7% |
| Q3 2024 | 156 | -1.1% | +14.7% |
| Q2 2024 | 158 | +18.7% | +9.9% |
| Q1 2024 | 133 | +1.6% | -2.3% |
| Q4 2023 | 131 | -3.8% | -3.9% |
| Q3 2023 | 136 | -5.3% | +25.8% |
| Q2 2023 | 144 | +5.6% | +13.6% |
| Q1 2023 | 136 | -0.1% | +6.6% |
| Q4 2022 | 136 | +25.9% | +15.6% |
| Q3 2022 | 108 | -14.5% | -8.8% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot